AUDENTES THERAPEUTICS, INC. Inactive Instrument
Audentes Therapeutics, Inc.
Equities
US05070R1041
Biotechnology & Medical Research
Presenter SpeechUnknown Analyst (Analysts)So good morning, everybody. Thanks for being here. I...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.
| 1st Jan change | Capi. | |
|---|---|---|
| +9.53% | 114B | |
| +11.54% | 104B | |
| -13.94% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.36% | 17.89B | |
| +7.26% | 14.28B | |
| +35.56% | 12.55B |
